Sinovac Biotech Ltd.

SVA · NASDAQ
Analyze with AI
6/30/2024
12/31/2023
6/30/2023
12/31/2022
Market Cap$644,461$644,438$644,261$643,780
- Cash$1,072,350$1,270,131$1,643,026$4,278,124
+ Debt$324,508$298,983$263,185$74,673
Enterprise Value-$103,381-$326,710-$735,580-$3,559,671
Revenue$307,865$140,404$280,471
% Growth119.3%-49.9%
Gross Profit$307,865-$48,005-$149,623
% Margin100%-34.2%-53.3%
EBITDA-$26,832$20,803-$999,623
% Margin-8.7%14.8%-356.4%
Net Income-$116,836$16,918-$370,646
% Margin-38%12%-132.2%
EPS Diluted-1.170.15-3.73
% Growth-880%104%
Operating Cash Flow$146,009-$39,991$151,773
Capital Expenditures-$52,746-$92,942-$149,995
Free Cash Flow$93,263-$132,933$1,778
Sinovac Biotech Ltd. (SVA) Financial Statements & Key Stats | AlphaPilot